Tag: COVID-19

The U.S will open its land borders for fully vaccinated travelers.

By Zolan Kanno-Youngs and Emily Cochrane

Read the full article from The New York Times, here.

The lifting of the bans will effectively mark the reopening of the United States to travelers and tourism, signaling a new phase in the recovery from the pandemic after the country closed its borders for nearly 19 months.

But the new requirements also indicate that the United States will welcome only visitors who are vaccinated. Unvaccinated travelers will continue to be banned from crossing the borders with Mexico or Canada, officials said. Those who were never banned from traveling across the land borders, including commercial drivers and students, will also need to show proof of vaccination when crossing starting in January, giving them some time to adjust to the new rules, officials said.

Moderna argues the F.D.A. should authorize a half-dose of its vaccine as a booster.

By Sharon LaFraniere

Read the full article from The New York Times, here.

Moderna cited the rate of breakthrough infections, “real world evidence of reduced effectiveness against the Delta variant,” and falling levels of neutralizing antibodies from its vaccine six to eight months after a second dose. The company said its clinical trial studies showed that a third injection boosted antibody levels — one measure of the immune system’s response — higher than what they had been before the second dose.

The rate of Covid-19 cases is dropping nationally but rising in these 5 states

By Aya Elamroussi and Holly Yan

Read the full article from CNN, here.

In 45 states, the rates of new Covid-19 cases either declined or stayed relatively steady this past week compared to the previous week, according to data Saturday from Johns Hopkins University.
Five states — Montana, Colorado, Minnesota, Michigan and Pennsylvania — had at least 10% more new cases this past week compared to the previous week.

Merck requests FDA authorization for COVID-19 antiviral pill

By Joseph Choi

Read the full article from The Hill, here.

Merck has said that its pill, which targets the enzyme that allows the COVID-19 virus to make copies of itself, is likely effective against COVID-19 variants, including the highly infectious delta variant.

The U.S. government already has a supply agreement with Merck to acquire about 1.7 million courses of molnupiravir if it receives emergency use authorization from the FDA.

As Biden’s vaccinate-or-test mandate approaches, questions arise over enforcement

By Heidi Przybyla and Laura Strickler

Read the full article from NBC News, here.

President Joe Biden says his sweeping Covid-19 vaccination and testing mandate will boost the economy and save lives, but as businesses prepare for the new requirement, they’re wondering not only what will be in the regulation, but how it will be enforced.

The mandate, which will apply to organizations with at least 100 employees and cover an estimated 80 million workers, has already drawn threats of lawsuits from two dozen Republican attorneys general and prompted some people to vow to quit their jobs. But a greater challenge for the administration could lie within the agency tasked with ensuring compliance.

Moderna, Racing for Profits, Keeps Covid Vaccine Out of Reach of Poor

By Rebecca Robbins

Read the full article from The New York Times, here.

Moderna, whose coronavirus vaccine appears to be the world’s best defense against Covid-19, has been supplying its shots almost exclusively to wealthy nations, keeping poorer countries waiting and earning billions in profit.

After developing a breakthrough vaccine with the financial and scientific support of the U.S. government, Moderna has shipped a greater share of its doses to wealthy countries than any other vaccine manufacturer, according to Airfinity, a data firm that tracks vaccine shipments.